Skip to content

STENAPHAR

Absorbed by MULTIPHARMA on 12-06-2025 KBO/BCE: BE 0467.037.380

Lifetime

18 annual accounts with figures on one time axis, 25 filings since 2000
peak of €145,935 in 2024
€145,935▲ 11×
lowest -€14,893 in 2008
€99,140▲ €100,256
peak of €199,242 in 2024
€199,242▲ 99.0%
€94,394▲ 14.5%
peak of 0.2 FTE in 2007
-not published
Board2 names since 2023
1 director
Owners
100%
Documentsfilings and deeds
23-06-202538 days before the deadline
2024financial year
Gross margin from €13,054 to €145,935Profit of €99,140, after a lossRegistered-office move 22-04 changes role from manager to director 29-021 director appointed, 1 statutory auditor appointed, 1 resign… 08-02Equity from €100,102 to €199,242

Key points

from the 2024 annual accounts, the last ones filed

Equity

€199,242 ▲ 99.0%
€100,0002023€199,0002024

Equity rose in 2024 from €100,102 to €199,242.

Liquidity

3.11 was 2.04 in 2023

Short-term debts rose from €82,462 to €94,394.

Filings

25 annual accounts since 2000
AprilJune31 JulyOctober200020102020

Eight of the last ten came late. The 2019 accounts came in latest, 101 days after the end of the period.

Board and ownership

Director
Auditor,
Board & ownership

Recent changes

Merger: absorbed by MULTIPHARMA Dissolution of the company · Dissolved without liquidation · MULTIPHARMA holds all the shares · Gazette deed
Merger proposal: to be absorbed by MULTIPHARMA Gazette deed
Registered-office move Gazette deed
changes role from manager to director Discharge granted to · General meeting of 12-12-2023 · Gazette deed
All 38 events

Official details

Source: KBO
Status
Absorbed by MULTIPHARMAmerger by absorption, April 2025
Activity
“L'achat, la vente, la préparation de produits pharmaceutiques, diététiques, homéopathiques;” (deed in French)From the articles, 6 activitiesNo NACE code in the KBO
Financial year end
31 December
Peppol
Not found in the Peppol Directory
Company details

Annual accounts 2024

≈ €380,000estimated
€293,635▲ 60.8%
Filing
Filed on 23-06-2025
Financials

Insights on STENAPHAR

Absorbed by MULTIPHARMA in April 2025. The last annual accounts are for financial year 2024. The company was dissolved without liquidation.

Sources: KBO register, filings at the National Bank, Belgian Official Gazette. Click a figure with a dotted line for the item and the filing.

Key facts about STENAPHAR

What is the company number of STENAPHAR?
The company number of STENAPHAR is 0467.037.380. The VAT number is the same number with BE in front: BE 0467.037.380.
What is the legal form of STENAPHAR?
The KBO register gives STENAPHAR the legal form “SRL”.
Is STENAPHAR still active?
No. Absorbed in a merger on 12-06-2025.Company details
What is the turnover of STENAPHAR?
The turnover in financial year 2024 is about €380,000. This figure is estimated from the gross margin of €145,935 and 1,393 comparable companies of the same size. It probably lies between €230,000 and €710,000. It is a rough estimate. In financial year 2022 turnover was €485,237.Financials
Is STENAPHAR profitable?
In financial year 2024, STENAPHAR made a profit of €99,140.
Where can I find the annual accounts of STENAPHAR?
STENAPHAR filed 25 annual accounts with the National Bank of Belgium, the latest for financial year 2024.

Next steps

Keep this company with today's facts in a case file.